Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression
Authors:
Open Access
- 8 June 2015
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (26) , 22081-22097
Abstract
Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regressionKeywords
This publication has 57 references indexed in Scilit:
- Cancer prevention and therapy through the modulation of the tumor microenvironmentSeminars in Cancer Biology, 2015
- The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancerOncotarget, 2014
- Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatmentBreast Cancer Research, 2014
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival AnalysisAdvances in Therapy, 2013
- Targeting Tumor Stroma: Exploiting Apoptotic PrimingOncotarget, 2012
- PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancerCarcinogenesis, 2011
- Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast CancerJournal of Clinical Oncology, 2011
- Stromal gene expression predicts clinical outcome in breast cancerNature Medicine, 2008
- The Partial Agonist Activity of Antagonist-Occupied Steroid Receptors Is Controlled by a Novel Hinge Domain-Binding Coactivator L7/SPA and the Corepressors N-CoR or SMRTMolecular Endocrinology, 1997
- Dimerization of mammalian progesterone receptors occurs in the absence of DNA and is related to the release of the 90-kDa heat shock protein.Proceedings of the National Academy of Sciences, 1991